Is Sonoma Pharmaceuticals Inc (SNOA) overvalued? · rev $19.5M
Sonoma Pharmaceuticals Inc (SNOA) is a drug manufacturers - specialty & generic company listed on US.
This page asks whether Sonoma Pharmaceuticals Inc (SNOA) looks expensive on cached numbers — not a short thesis.
Latest reported SNOA revenue for 2026-03-31 was $19.5M. Net income was -$3.2M. Revenue was up 36.7% from 2025-03-31 to 2026-03-31. SNOA currently screens at market cap $4.9M.
SNOA currently screens at market cap $4.9M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next SNOA 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the SNOA stock page for the full model, not this heading.
Not investment advice.